Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

SB 9200, a novel agonist of innate immunity, shows potent antiviral activity against resistant HCV variants.

Jones M, Cunningham ME, Wing P, DeSilva S, Challa R, Sheri A, Padmanabhan S, Iyer RP, Korba BE, Afdhal N, Foster GR.

J Med Virol. 2017 Sep;89(9):1620-1628. doi: 10.1002/jmv.24809. Epub 2017 May 23.

PMID:
28303593
2.

Treatment of norovirus infections: moving antivirals from the bench to the bedside.

Kaufman SS, Green KY, Korba BE.

Antiviral Res. 2014 May;105:80-91. doi: 10.1016/j.antiviral.2014.02.012. Epub 2014 Feb 25. Review.

3.

Thiazolides as novel antiviral agents. 2. Inhibition of hepatitis C virus replication.

Stachulski AV, Pidathala C, Row EC, Sharma R, Berry NG, Lawrenson AS, Moores SL, Iqbal M, Bentley J, Allman SA, Edwards G, Helm A, Hellier J, Korba BE, Semple JE, Rossignol JF.

J Med Chem. 2011 Dec 22;54(24):8670-80. doi: 10.1021/jm201264t. Epub 2011 Nov 21.

PMID:
22059983
4.

Thiazolides as novel antiviral agents. 1. Inhibition of hepatitis B virus replication.

Stachulski AV, Pidathala C, Row EC, Sharma R, Berry NG, Iqbal M, Bentley J, Allman SA, Edwards G, Helm A, Hellier J, Korba BE, Semple JE, Rossignol JF.

J Med Chem. 2011 Jun 23;54(12):4119-32. doi: 10.1021/jm200153p. Epub 2011 May 23.

5.

Tricyclic 2'-C-modified nucleosides as potential anti-HCV therapeutics.

Wauchope OR, Tomney MJ, Pepper JL, Korba BE, Seley-Radtke KL.

Org Lett. 2010 Oct 15;12(20):4466-9. doi: 10.1021/ol101482h.

6.

Orally bioavailable anti-HBV dinucleotide acyloxyalkyl prodrugs.

Coughlin JE, Padmanabhan S, Zhang G, Kirk CJ, Govardhan CP, Korba BE, O'Loughlin K, Green CE, Mirsalis J, Morrey JD, Iyer RP.

Bioorg Med Chem Lett. 2010 Mar 1;20(5):1783-6. doi: 10.1016/j.bmcl.2010.01.010. Epub 2010 Jan 11.

7.

Alkoxyalkyl esters of 9-(s)-(3-hydroxy-2-phosphonomethoxypropyl) adenine are potent and selective inhibitors of hepatitis B virus (HBV) replication in vitro and in HBV transgenic mice in vivo.

Morrey JD, Korba BE, Beadle JR, Wyles DL, Hostetler KY.

Antimicrob Agents Chemother. 2009 Jul;53(7):2865-70. doi: 10.1128/AAC.00114-09. Epub 2009 Apr 27.

8.

The octadecyloxyethyl ester of (S)-9-[3-hydroxy-2-(phosphonomethoxy) propyl]adenine is a potent and selective inhibitor of hepatitis C virus replication in genotype 1A, 1B, and 2A replicons.

Wyles DL, Kaihara KA, Korba BE, Schooley RT, Beadle JR, Hostetler KY.

Antimicrob Agents Chemother. 2009 Jun;53(6):2660-2. doi: 10.1128/AAC.01546-08. Epub 2009 Mar 16.

9.

Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide.

Korba BE, Elazar M, Lui P, Rossignol JF, Glenn JS.

Antimicrob Agents Chemother. 2008 Nov;52(11):4069-71. doi: 10.1128/AAC.00078-08. Epub 2008 Aug 18.

10.

Fluorinated methylenecyclopropane analogues of nucleosides. Synthesis and antiviral activity of (Z)- and (E)-9-{[(2-fluoromethyl-2-hydroxymethyl)-cyclopropylidene]methyl}adenine and -guanine.

Li C, Prichard MN, Korba BE, Drach JC, Zemlicka J.

Bioorg Med Chem. 2008 Mar 1;16(5):2148-55. Epub 2007 Dec 5. Erratum in: Bioorg Med Chem. 2009 Jan 1;17(1):427.

11.

Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication.

Korba BE, Montero AB, Farrar K, Gaye K, Mukerjee S, Ayers MS, Rossignol JF.

Antiviral Res. 2008 Jan;77(1):56-63. Epub 2007 Sep 4.

PMID:
17888524
12.

Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections.

Painter GR, Almond MR, Trost LC, Lampert BM, Neyts J, De Clercq E, Korba BE, Aldern KA, Beadle JR, Hostetler KY.

Antimicrob Agents Chemother. 2007 Oct;51(10):3505-9. Epub 2007 Jul 23. Erratum in: Antimicrob Agents Chemother. 2007 Dec;51(12):4538.

13.
14.

Pegylated arginine deiminase lowers hepatitis C viral titers and inhibits nitric oxide synthesis.

Izzo F, Montella M, Orlando AP, Nasti G, Beneduce G, Castello G, Cremona F, Ensor CM, Holtzberg FW, Bomalaski JS, Clark MA, Curley SA, Orlando R, Scordino F, Korba BE.

J Gastroenterol Hepatol. 2007 Jan;22(1):86-91.

PMID:
17201887
15.

Antiviral activities of novel 5-phosphono-pent-2-en-1-yl nucleosides and their alkoxyalkyl phosphonoesters.

Choo H, Beadle JR, Kern ER, Prichard MN, Keith KA, Hartline CB, Trahan J, Aldern KA, Korba BE, Hostetler KY.

Antimicrob Agents Chemother. 2007 Feb;51(2):611-5. Epub 2006 Nov 27.

16.

Clevudine: a potent inhibitor of hepatitis B virus in vitro and in vivo.

Korba BE, Furman PA, Otto MJ.

Expert Rev Anti Infect Ther. 2006 Aug;4(4):549-61. Review.

PMID:
17009935
17.
18.

Clevudine inhibits hepatitis delta virus viremia: a pilot study of chronically infected woodchucks.

Casey J, Cote PJ, Toshkov IA, Chu CK, Gerin JL, Hornbuckle WE, Tennant BC, Korba BE.

Antimicrob Agents Chemother. 2005 Oct;49(10):4396-9.

19.

Nucleotide analogs as novel anti-hepatitis B virus agents.

Iyer RP, Padmanabhan S, Zhang G, Morrey JD, Korba BE.

Curr Opin Pharmacol. 2005 Oct;5(5):520-8. Review.

PMID:
16087397
20.

Antiviral effect of oral administration of tenofovir disoproxil fumarate in woodchucks with chronic woodchuck hepatitis virus infection.

Menne S, Cote PJ, Korba BE, Butler SD, George AL, Tochkov IA, Delaney WE 4th, Xiong S, Gerin JL, Tennant BC.

Antimicrob Agents Chemother. 2005 Jul;49(7):2720-8.

21.

Korean medicinal plant extracts exhibit antiviral potency against viral hepatitis.

Jacob JR, Korba BE, You JE, Tennant BC, Kim YH.

J Altern Complement Med. 2004 Dec;10(6):1019-26.

PMID:
15673997
22.

Enhancement of antiviral activity against hepatitis C virus in vitro by interferon combination therapy.

Okuse C, Rinaudo JA, Farrar K, Wells F, Korba BE.

Antiviral Res. 2005 Jan;65(1):23-34.

PMID:
15652968
23.

Clevudine therapy with vaccine inhibits progression of chronic hepatitis and delays onset of hepatocellular carcinoma in chronic woodchuck hepatitis virus infection.

Korba BE, Cote PJ, Menne S, Toshkov I, Baldwin BH, Wells FV, Tennant BC, Gerin JL.

Antivir Ther. 2004 Dec;9(6):937-52.

PMID:
15651753
24.

Hepatocellular carcinoma in the woodchuck model of hepatitis B virus infection.

Tennant BC, Toshkov IA, Peek SF, Jacob JR, Menne S, Hornbuckle WE, Schinazi RD, Korba BE, Cote PJ, Gerin JL.

Gastroenterology. 2004 Nov;127(5 Suppl 1):S283-93. Review.

PMID:
15508096
25.

Suppression of lamivudine-resistant B-domain mutants by adefovir dipivoxil in the woodchuck hepatitis virus model.

Jacob JR, Korba BE, Cote PJ, Toshkov I, Delaney WE 4th, Gerin JL, Tennant BC.

Antiviral Res. 2004 Aug;63(2):115-21.

PMID:
15302140
26.

Integration of woodchuck hepatitis and N-myc rearrangement determine size and histologic grade of hepatic tumors.

Jacob JR, Sterczer A, Toshkov IA, Yeager AE, Korba BE, Cote PJ, Buendia MA, Gerin JL, Tennant BC.

Hepatology. 2004 Apr;39(4):1008-16.

PMID:
15057905
28.

Viral pharmacodynamic model for (-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine (emtricitabine) in chronically infected woodchucks.

Hurwitz SJ, Tennant BC, Korba BE, Liberman I, Gerin JL, Schinazi RF.

Antivir Chem Chemother. 2002 May;13(3):165-76.

PMID:
12448689
29.

Mutations in the conserved woodchuck hepatitis virus polymerase FLLA and YMDD regions conferring resistance to lamivudine.

Tatti KM, Korba BE, Stang HL, Peek S, Gerin JL, Tennant BC, Schinazi RF.

Antiviral Res. 2002 Jul;55(1):141-50.

PMID:
12076758
31.

Novel ring-expanded nucleoside analogs exhibit potent and selective inhibition of hepatitis B virus replication in cultured human hepatoblastoma cells.

Sood RK, Bhadti VS, Fattom AI, Naso RB, Korba BE, Kern ER, Chen HM, Hosmane RS.

Antiviral Res. 2002 Feb;53(2):159-64.

PMID:
11750942
32.

Antiviral activity of clevudine [L-FMAU, (1-(2-fluoro-5-methyl-beta, L-arabinofuranosyl) uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmota monax).

Peek SF, Cote PJ, Jacob JR, Toshkov IA, Hornbuckle WE, Baldwin BH, Wells FV, Chu CK, Gerin JL, Tennant BC, Korba BE.

Hepatology. 2001 Jan;33(1):254-66.

PMID:
11124844
33.

Temporal pathogenesis of experimental neonatal woodchuck hepatitis virus infection: increased initial viral load and decreased severity of acute hepatitis during the development of chronic viral infection.

Cote PJ, Toshkov I, Bellezza C, Ascenzi M, Roneker C, Ann Graham L, Baldwin BH, Gaye K, Nakamura I, Korba BE, Tennant BC, Gerin JL.

Hepatology. 2000 Oct;32(4 Pt 1):807-17.

PMID:
11003627
34.

Enhanced antiviral benefit of combination therapy with lamivudine and alpha interferon against WHV replication in chronic carrier woodchucks.

Korba BE, Cote P, Hornbuckle W, Schinazi R, Gangemi JD, Tennant BC, Gerin JL.

Antivir Ther. 2000 Jun;5(2):95-104.

PMID:
10971862
35.

Antiviral activities of oral 1-O-hexadecylpropanediol-3-phosphoacyclovir and acyclovir in woodchucks with chronic woodchuck hepatitis virus infection.

Hostetler KY, Beadle JR, Hornbuckle WE, Bellezza CA, Tochkov IA, Cote PJ, Gerin JL, Korba BE, Tennant BC.

Antimicrob Agents Chemother. 2000 Jul;44(7):1964-9.

36.

Effect of oral administration of emtricitabine on woodchuck hepatitis virus replication in chronically infected woodchucks.

Korba BE, Schinazi RF, Cote P, Tennant BC, Gerin JL.

Antimicrob Agents Chemother. 2000 Jun;44(6):1757-60.

38.

Enhanced antiviral benefit of combination therapy with lamivudine and famciclovir against WHV replication in chronic WHV carrier woodchucks.

Korba BE, Cote P, Hornbuckle W, Schinazi R, Gerin JL, Tennant BC.

Antiviral Res. 2000 Jan;45(1):19-32. Erratum in: Antiviral Res 2000 Feb;45(2):155-6.

PMID:
10774587
39.

Preclinical investigation of L-FMAU as an anti-hepatitis B virus agent.

Chu CK, Boudinot FD, Peek SF, Hong JH, Choi Y, Korba BE, Gerin JL, Cote PJ, Tennant BC, Cheng YC.

Antivir Ther. 1998;3(Suppl 3):113-21. Review.

PMID:
10726061
40.

Transgenic mice as a chemotherapeutic model for hepatitis B virus infection.

Morrey JD, Korba BE, Sidwell RW.

Antivir Ther. 1998;3(Suppl 3):59-68. Review.

PMID:
10726056
41.

Effects of age and viral determinants on chronicity as an outcome of experimental woodchuck hepatitis virus infection.

Cote PJ, Korba BE, Miller RH, Jacob JR, Baldwin BH, Hornbuckle WE, Purcell RH, Tennant BC, Gerin JL.

Hepatology. 2000 Jan;31(1):190-200.

PMID:
10613745
42.

Utilization of transgenic mice replicating high levels of hepatitis B virus for antiviral evaluation of lamivudine.

Morrey JD, Bailey KW, Korba BE, Sidwell RW.

Antiviral Res. 1999 Jun;42(2):97-108.

PMID:
10389653
44.

Robustaflavone, a potential non-nucleoside anti-hepatitis B agent.

Zembower DE, Lin YM, Flavin MT, Chen FC, Korba BE.

Antiviral Res. 1998 Aug;39(2):81-8.

PMID:
9806485
45.

Pharmacodynamics of (-)-beta-2',3'-dideoxy-3'-thiacytidine in chronically virus-infected woodchucks compared to its pharmacodynamics in humans.

Hurwitz SJ, Tennant BC, Korba BE, Gerin JL, Schinazi RF.

Antimicrob Agents Chemother. 1998 Nov;42(11):2804-9. Erratum in: Antimicrob Agents Chemother 1998 Dec;42(12):3337.

46.

Antiviral activity and toxicity of fialuridine in the woodchuck model of hepatitis B virus infection.

Tennant BC, Baldwin BH, Graham LA, Ascenzi MA, Hornbuckle WE, Rowland PH, Tochkov IA, Yeager AE, Erb HN, Colacino JM, Lopez C, Engelhardt JA, Bowsher RR, Richardson FC, Lewis W, Cote PJ, Korba BE, Gerin JL.

Hepatology. 1998 Jul;28(1):179-91.

PMID:
9657111
47.

Antiviral activity of a conjugate of adenine-9-beta-D-arabinofuranoside 5'-monophosphate and a 9 kDa fragment of arabinogalactan.

Josephson L, Rutkowski JV, Paul K, Frigo T, Korba BE, Tennant B, Groman EV.

Antivir Ther. 1996 Aug;1(3):147-56.

PMID:
11322248
48.
49.
50.

Supplemental Content

Loading ...
Support Center